ZA201904431B - Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases - Google Patents
Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseasesInfo
- Publication number
- ZA201904431B ZA201904431B ZA2019/04431A ZA201904431A ZA201904431B ZA 201904431 B ZA201904431 B ZA 201904431B ZA 2019/04431 A ZA2019/04431 A ZA 2019/04431A ZA 201904431 A ZA201904431 A ZA 201904431A ZA 201904431 B ZA201904431 B ZA 201904431B
- Authority
- ZA
- South Africa
- Prior art keywords
- neurodegenerative
- cell activation
- early detection
- glial cell
- neuroinflammatory diseases
- Prior art date
Links
- 208000036110 Neuroinflammatory disease Diseases 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title 1
- 230000007277 glial cell activation Effects 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 108010056102 CD100 antigen Proteins 0.000 abstract 2
- 102100027744 Semaphorin-4D Human genes 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000010176 18-FDG-positron emission tomography Methods 0.000 abstract 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004190 glucose uptake Effects 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000002314 neuroinflammatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461945P | 2017-02-22 | 2017-02-22 | |
| PCT/US2018/018794 WO2018156509A1 (en) | 2017-02-22 | 2018-02-20 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201904431B true ZA201904431B (en) | 2024-11-27 |
Family
ID=63253999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/04431A ZA201904431B (en) | 2017-02-22 | 2019-07-05 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190383836A1 (enExample) |
| EP (1) | EP3585435A4 (enExample) |
| JP (1) | JP7626416B2 (enExample) |
| KR (1) | KR102533921B1 (enExample) |
| CN (1) | CN110325213A (enExample) |
| AU (1) | AU2018225493B2 (enExample) |
| BR (1) | BR112019017367A2 (enExample) |
| CA (1) | CA3050328A1 (enExample) |
| IL (1) | IL267940B2 (enExample) |
| MX (1) | MX2019009986A (enExample) |
| RU (1) | RU2766341C2 (enExample) |
| SG (1) | SG11201906670PA (enExample) |
| WO (1) | WO2018156509A1 (enExample) |
| ZA (1) | ZA201904431B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| CA3231551A1 (en) * | 2021-09-27 | 2023-03-30 | Maurice Zauderer | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| AU2024243083A1 (en) * | 2023-04-03 | 2025-11-20 | Sialbio Co., Ltd. | Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| KR101603917B1 (ko) * | 2008-05-09 | 2016-03-17 | 애브비 인코포레이티드 | 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도 |
| CN104168956A (zh) * | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2018
- 2018-02-20 WO PCT/US2018/018794 patent/WO2018156509A1/en not_active Ceased
- 2018-02-20 EP EP18757318.3A patent/EP3585435A4/en active Pending
- 2018-02-20 RU RU2019122337A patent/RU2766341C2/ru active
- 2018-02-20 MX MX2019009986A patent/MX2019009986A/es unknown
- 2018-02-20 CN CN201880013208.3A patent/CN110325213A/zh active Pending
- 2018-02-20 KR KR1020197027287A patent/KR102533921B1/ko active Active
- 2018-02-20 US US16/488,123 patent/US20190383836A1/en not_active Abandoned
- 2018-02-20 BR BR112019017367A patent/BR112019017367A2/pt unknown
- 2018-02-20 SG SG11201906670PA patent/SG11201906670PA/en unknown
- 2018-02-20 IL IL267940A patent/IL267940B2/en unknown
- 2018-02-20 JP JP2019566047A patent/JP7626416B2/ja active Active
- 2018-02-20 AU AU2018225493A patent/AU2018225493B2/en active Active
- 2018-02-20 CA CA3050328A patent/CA3050328A1/en active Pending
-
2019
- 2019-07-05 ZA ZA2019/04431A patent/ZA201904431B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018156509A1 (en) | 2018-08-30 |
| MX2019009986A (es) | 2019-10-14 |
| EP3585435A1 (en) | 2020-01-01 |
| JP2020510845A (ja) | 2020-04-09 |
| AU2018225493A1 (en) | 2019-08-01 |
| NZ755446A (en) | 2025-06-27 |
| EP3585435A4 (en) | 2020-12-16 |
| CN110325213A (zh) | 2019-10-11 |
| RU2019122337A3 (enExample) | 2021-06-09 |
| JP7626416B2 (ja) | 2025-02-04 |
| IL267940A (en) | 2019-09-26 |
| IL267940B2 (en) | 2025-04-01 |
| RU2019122337A (ru) | 2021-03-23 |
| RU2766341C2 (ru) | 2022-03-15 |
| IL267940B1 (en) | 2024-12-01 |
| SG11201906670PA (en) | 2019-08-27 |
| KR20190120784A (ko) | 2019-10-24 |
| BR112019017367A2 (pt) | 2020-04-14 |
| CA3050328A1 (en) | 2018-08-30 |
| AU2018225493B2 (en) | 2025-03-06 |
| US20190383836A1 (en) | 2019-12-19 |
| KR102533921B1 (ko) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201904431B (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| PH12019501146A1 (en) | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| EP3405896A4 (en) | SYSTEMS AND METHOD FOR IMPROVED DIAGNOSIS OF ILLNESSES | |
| WO2012054639A3 (en) | Nmr systems and methods for the rapid detection of analytes | |
| EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 | |
| EP4282484A3 (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases | |
| EP3270178C0 (en) | A system and method for determining optimal operating parameters for medical imaging | |
| EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
| CA2951016C (en) | Prostate cancer detection kit or device, and detection method | |
| EP3432050A4 (en) | DISPLAY IMAGING SYSTEM AND METHOD AND VEHICLE WITH THE SYSTEM | |
| EP3761605A4 (en) | VEHICLE DIAGNOSTIC PROCEDURE, DEVICE RELATED TO THE SYSTEM | |
| PL3523639T3 (pl) | Odczynniki wykrywające i układy elektrod do elementów diagnostycznych testów wieloanalitowych oraz sposoby ich zastosowania | |
| MA43151A (fr) | Anticorps monoclonaux spécifiques pour le sérogroupe x de n. meningitidis et leurs utilisations dans le diagnostic | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| NZ707116A (en) | Ly75 as cancer therapeutic and diagnostic target | |
| WO2015042326A3 (en) | Methods for detection and treatment of neurodegenerative diseases | |
| WO2014042828A3 (en) | Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia | |
| EP3487524A4 (en) | HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES | |
| IL263024A (en) | Blood sample analysis method and system, for determining diabetes | |
| MX2021009528A (es) | Prueba de diagnostico basada en fragmento de rgma. | |
| IL272484A (en) | Systems and methods for improving disease diagnosis using measured test substances | |
| FR3037147B1 (fr) | Procede et dispositif de reflectometrie pour le diagnostic de cables en fonctionnement. | |
| WO2016014799A9 (en) | Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy | |
| BR112016028838A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer |